New Study Results Reaffirms Diachrome(R) Significantly Improves Cardiovascular Disease Risk Factors in People With Type 2 Diabetes
Posted on: Monday, 18 July 2005, 15:00 CDT
Results of Clinical Trial Examining Effects of Diachrome on Atherogenic Index of Plasma Presented at 2nd International Symposium on Triglycerides and HDL
Nutrition 21, Inc. (Nasdaq: NXXI) reported today results from a new clinical study that add to the growing body of clinical data demonstrating that daily supplementation with Diachrome(R), a combination of chromium picolinate and biotin, can significantly reduce cardiovascular disease risk factors in people with type 2 diabetes. Findings from the randomized double-blind, placebo-controlled trial, were presented at the 2nd International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and the Metabolic Syndrome in New York, a meeting organized by the Giovanni Lorenzini Medical Foundation that is attended by both U.S. and international cardiologists and lipid specialists.
The study results presented include an analysis of subjects with type 2 diabetes who were moderately obese and taking oral antidiabetic medications. When Diachrome was added to daily treatment regimens, the atherogenic index of plasma (AIP), a predictive marker for cardiovascular disease that examines triglyceride and HDL cholesterol levels (good cholesterol), was significantly lower compared with the placebo group. The AIP in the Diachrome group dropped from 1.15 to 1.06, while it increased from 1.27 to 1.55 in the placebo group. A significant difference in triglycerides and cholesterol levels was also observed between the groups.
"These results support previous findings that Diachrome can serve as a safe and effective nutritional adjunct to medication in helping to lower triglyceride and cholesterol levels in people with type 2 diabetes," said study investigator Jeffrey Geohas, Medical Director, Chicago Research Center. "The ability for Diachrome to reduce these risk factors is important in this population because heart disease is the leading cause of death in patients who suffer from diabetes," said Dr. Geohas.
Nutrition 21, Inc. conducted the study in collaboration with the Chicago Research Center. "This study underscores the promise of Diachrome in helping to prevent cardiovascular disease in people with type 2 diabetes," said Gail Montgomery, president and CEO of Nutrition 21. "As we share the wealth of clinical data demonstrating the benefits of Diachrome for people with type 2 diabetes, we anticipate that physicians will be eager to incorporate the product into clinical practice."
Diachrome is a nutritional supplement specifically formulated for people with diabetes. It contains 600 mcg of chromium as Chromax(R) chromium picolinate and 2 mg of biotin. These two compounds are both Generally Recognized as Safe (GRAS) for use as ingredients in food and supplements. It is available for purchase by calling 1-866-DIACHROME or at www.diachrome.com.
About the Atherogenic Index of Plasma
AIP is an index used to measure the atherogenicity of plasma by examining the ratio of triglycerides to HDL cholesterol (good cholesterol). It identifies the risk for atherogenesis (fat build up in the arteries), particularly in diabetes patients and is recognized as a predictor for heart attack. The measurement reflects the delicate balance of metabolic interactions with the whole lipoprotein complex. Physicians currently utilize AIP in clinical practice to quantify response to therapeutic interventions.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome, which is available through diabetes educators or at www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.
Source: Business Wire
Related Articles
- Accelr8 Announces Study Results With Rapid ESBL Test for Broad Resistance in Gram-Negative Pathogens
- Journal of Neuroimmunology Publishes Study Results Showing That Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack By the Human Immune System
- Novavax Reports Positive Pre-Clinical Study Results From Live Virus Challenge to Pandemic Flu Vaccine
- Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
- Parkinson's Disease Study Results Released
- Diabetes on the Rise Among America's Youth, Study Shows
- St. Jude Medical Announces Publication of OPTIC Clinical Study Results in JAMA; Study May Hold the Key to Reducing Shocks in ICD Patients
- Inovio Study Results of Gene-Based Therapies for HIV and Vascular Disease Published in Scientific Journals; Articles Published in Collaboration With Boehringer Ingelheim and Chiron Corporation
- Phase I ProCord Study Results Published in the Journal of Neurosurgery: Spine, September 2005 Issue; ProCord Phase I Study Results Suggest Evidence of Safety
- Large Clinical Study Results Show Pramipexole Rapidly Relieves Restless Legs Syndrome Symptoms and Improves Sleep
 |
 |
User Comments (0)
RSS Feeds